Altium Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Altium Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-41,485	Closed	-$4.23M	–	85
2023 Q2	$4.23M	Buy	41,485 +6,485	+19%	+$614K	3.2%	11
2023 Q1	$3.18M	Buy	+35,000	New	+$2.05M	1.77%	20

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Altium Capital Management's RETA Position: Q3 2023 in Review

Altium Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 41,485 shares — an estimated $4.23M sold.

Altium Capital Management first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $4.23M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Altium Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Altium Capital Management sold 41,485 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $4.23M.
Altium Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Altium Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.23M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Altium Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.